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Abstract
Background: Both prophylaxis and treatment of venous thromboembolism (VTE:
deep venous thrombosis (DVT) and pulmonary emboli (PE)) with anticoagulants are
associated with significant risks of major and fatal hemorrhage. Anticoagulation
treatment of VTE has been the standard of care in the USA since before 1962 when
the U.S. Food and Drug Administration began requiring randomized controlled clinical
trials (RCTs) showing efficacy, so efficacy trials were never required for FDA approval. In
clinical trials of ‘high VTE risk’ surgical patients before the 1980s, anticoagulant
prophylaxis was clearly beneficial (fatal pulmonary emboli (FPE) without anticoagulants
= 0.99%, FPE with anticoagulants = 0.31%). However, observational studies and RCTs of
‘high VTE risk’ surgical patients from the 1980s until 2010 show that FPE deaths
without anticoagulants are about one-fourth the rate that occurs during prophylaxis
with anticoagulants (FPE without anticoagulants = 0.023%, FPE while receiving
anticoagulant prophylaxis = 0.10%). Additionally, an FPE rate of about 0.012% (35/
28,400) in patients receiving prophylactic anticoagulants can be attributed to ‘rebound
hypercoagulation’ in the two months after stopping anticoagulants. Alternatives to
anticoagulant prophylaxis should be explored.
Methods and Findings: The literature concerning dietary influences on VTE
incidence was reviewed. Hypotheses concerning the etiology of VTE were critiqued
in relationship to the rationale for dietary versus anticoagulant approaches to
prophylaxis and treatment.
Epidemiological evidence suggests that a diet with ample fruits and vegetables and
little meat may substantially reduce the risk of VTE; vegetarian, vegan, or Mediterra-
nean diets favorably affect serum markers of hemostasis and inflammation. The valve
cusp hypoxia hypothesis of DVT/VTE etiology is consistent with the development of
VTE being affected directly or indirectly by diet. However, it is less consistent with the
rationale of using anticoagulants as VTE prophylaxis. For both prophylaxis and treat-
ment of VTE, we propose RCTs comparing standard anticoagulation with low VTE risk
diets, and we discuss the statistical considerations for an example of such a trial.
Conclusions: Because of (a) the risks of biochemical anticoagulation as anti-VTE
prophylaxis or treatment, (b) the lack of placebo-controlled efficacy data supporting
anticoagulant treatment of VTE, (c) dramatically reduced hospital-acquired FPE
incidence in surgical patients without anticoagulant prophylaxis from 1980 - 2010
relative to the 1960s and 1970s, and (d) evidence that VTE incidence and outcomes
may be influenced by diet, randomized controlled non-inferiority clinical trials are
proposed to compare standard anticoagulant treatment with potentially low VTE risk
diets. We call upon the U. S. National Institutes of Health and the U.K. National
Institute for Health and Clinical Excellence to design and fund those trials.
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The consensus view that DVT and VTE are hematological disorders arose shortly after
the Second World War and had become the new orthodoxy by the early 1960s. It still
dominates research and practice in the field. Essentially, this consensus added ‘hyper-
coagulability’ to the ‘stasis’ and ‘vessel wall injury’ thesis of Hunterian pathophysiology,
generating a set of loosely-defined terms that was misleadingly ascribed to Virchow
[1,2]. In support of that consensus, at least some inherited and acquired thrombophi-
lias (’hypercoagulability conditions’) appear to increase the incidence of VTE, though
this may indicate that thrombophilias aggravate rather than cause the disease. More-
over, there is an argument [3] that the so-called ‘Virchow’st r i a d ’ constitutes a useful
rule of thumb for managing patients. Strikingly, however, the consensus view arose
when anticoagulant therapy for thrombosis patients was becoming popular [4] and has
developed along with such therapy and with the subsequent deployment of thromboly-
tic agents [1,2]. It seems integral with the pharmaceutical approach to DVT/VTE pro-
phylaxis and treatment.
An alternative account of the etiology of DVT, the valve cusp hypoxia hypothesis
(VCHH), is rooted in the tradition of thought and practice initiated by Hunter and
traceable from Harvey through Virchow, Lister, Welch and a number of early 20
th cen-
tury investigators [1,2]. According to the VCHH, DVT may occur wherever sustained
non-pulsatile (streamline) venous blood flow leads to suffocating hypoxemia in the
valve pockets, resulting in hypoxic injury to and hence death of the inner (parietalis)
endothelium of the cusp leaflets. This injury activates the elk-1/egr-1 pathway, which
initiates many responses of endothelial cells to hypoxia and activates chemoattractant
and procoagulant factors [5]. (Briefly: elk-1 is a receptor tyrosine kinase stimulated by
hypoxia; it phosphorylates the zinc-finger transcription factor early growth response-1
(egr-1), which then activates downstream genes encoding factors directly or indirectly
involved in blood coagulation.) When normal pulsatile blood flow is restored, however
transiently, leukocytes and platelets are attracted by these factors and inevitably re-
enter the lately-affected valve pockets and marginate and sequestrate at the site of
injury, the inner/parietal surfaces of the valve cusps, whereupon local blood coagula-
tion (semi-solidification) is likely to be initiated.
Any subsequent period of non-pulsatile flow may kill the accumulated blood cells
marginated on the dying or dead valve pocket. These dead cells may then form the
core of a nascent thrombus. If periods of non-pulsatile and pulsatile flow continue to
alternate, serial deposition of white cells and fibrin may ensue, resulting in the charac-
teristic ‘Lines of Zahn’ morphology of a venous thrombus. Subsequently, only the
blood cells on the outermost layer of a thrombus are living.
The VCHH explains many of the recognized risk factors for DVT and accounts for
the morphology of thrombi. It also predicts that venous thrombi will readily embolize,
because the area of endothelium to which they are anchored, the valve cusp parietalis,
h a sb e c o m en e c r o t i cs oi tm a yb er e a d i l yd e t a c h e db yt h ef l o wo fb l o o dp a s tt h e
obstruction.
Compared with the Virchow’s triad hypothesis of DVT etiology, the VCHH better
explains what appears to be a marked reduction in the incidence of hospital-acquired
VTE (see below) following the introduction of early mobilization of post-operative
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vein blood flow (e.g., flexion and extension of the ankles, support hoses, and intermit-
tent pneumatic pressure leg devices). According to the VCHH, drugs that inhibit or
‘kill’ any part of the coagulation process might slow the progression of established
DVTs but would be ineffective in preventing the initiation of thrombi.
Problems with anticoagulant treatment for VTE
Bleeding
Regarding patients treated for VTE with standard anticoagulants, a recent meta-analysis
of published RCTs showed major and fatal bleeding rates of 1.8% and 0.2%, respectively
[6]. Older cohort studies report up to triple these rates [7-9]. Applying the range of
reported fatal bleeding rates for VTE treatment (0.2% - 0.6%) to an estimated 300,000-
1.2 million people treated for VTE worldwide per year (about half in the USA [10]), 600-
7,200 people per year suffer fatal bleeds from VTE anticoagulant treatment. There are
many more non-fatal major bleeds, some of which are permanently debilitating.
Anticoagulant prophylaxis for surgical patients increases the risk of major bleeding
[11]. VTE prevention trials report markedly different rates of major bleeding despite
similar patient populations and doses and durations of anticoagulant prophylaxis. For
instance, major bleeding with enoxaparin reportedly ranged from 0.1% to 3.1% in hip
arthroplasty trials and from 0.2% to 1.4% in kn e ea r t h r o p l a s t yt r i a l s. If surgical-site
bleeding is included in the definition of major bleeding, the reported rates have been
about 10-fold higher [12]. Major bleeding adversely affects overall mortality. In a meta-
analysis of trials comparing fondaparinux with LMWHs or placebos (major bleeding
incidence overall = 2.4%), the risk of death by 30 days was 7-fold higher among
patients with compared to those without a major bleeding event (8.6% versus 1.7%)
[13]. If the major bleeding is considered the cause of the higher death rate, 6.9% of
deaths in patients with major bleeds may be attributed to the bleeding (8.6% - 1.7% =
6.9%). Consequently, deaths of about 0.166% of anticoagulated patients are arguably
attributable to bleeding (0.069 × 0.024 = 0.00166). Given that at least 12 million medi-
cal and surgical patients worldwide receive prophylactic anticoagulants per year
[14,15], this means that approximately 20,000 people may die each year from complica-
tions of bleeding from prophylactic anticoagulants (0.00166 × 12 million = 19,872);
many more may suffer the consequences of hypovolemia.
Efficacy
Anticoagulant therapy for VTE became established as the standard of care in the 1940s
and 1950s before randomized trials were considered necessary to prove efficacy and
safety. A very small RCT comparing anticoagulants versus placebo for people with clin-
ical diagnoses of PE published in 1960 [4] has been used to justify anticoagulant ther-
apy. However, by current scientific standards, this study is highly flawed [10,16].
In 1962 when the U.S. Food and Drug Administration began requiring randomized
controlled clinical trials (RCTs) showing efficacy before approving drugs, anticoagula-
tion treatment of VTE was ‘grandfathered in’ with no rigorous efficacy trials ever
required. Only three small methodologically rigorous RCTs of patients with DVTs
[17-19] have compared standard anticoagulants with placebos or non-steroidal anti-
inflammatory drugs. Combining the data from these trials, 6/66 patients receiving
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died [10]. Consequently, standard anticoagulant treatment for VTE cannot be consid-
ered evidence-based to be effective [10,20].
Anticoagulant prophylaxis of ‘high VTE risk’ patients may increase fatal pulmonary
emboli (FPE) due to ‘rebound hypercoagulation’
Goldhaber and colleagues tracked the incidence of developing DVT or PE during or up
to 30 days after hospital discharge in about 80,000 patients admitted over a two year
period in Boston’s Brigham and Women’s Hospital. Out of 384 patients with hospital-
acquired VTE, 318 (82.8%) were potential candidates for prophylaxis (i.e., they had ≥2
VTE risk factors). Of prophylaxis candidates, 170 (53%) of those with hospital-acquired
VTE had received anticoagulants [21]. To estimate the influence of prophylactic antic-
oagulants in this study, we can use Goldhaber’s USA-wide estimates of hospitalized
patients that are at ‘high VTE risk’–32% [14] or 25,600/80,000 in the Brigham and
Women’s Hospital study – and the proportion of those at VTE risk who receive antic-
oagulant prophylaxis – 50% [14] or 12,800/25,600 in this study. According to these
estimates, ‘high VTE risk’ patients receiving anticoagulants in this population had a
non-significant trend toward a higher incidence of VTE (OR = 1.15, 95% CI = 0.92 -
1.44) [22].
More importantly in this chart study, out of 13 deaths attributed to hospital-acquired
FPE, 12 had received anticoagulant prophylaxis [21]. As above, assuming that 32% of
the hospitalized patients were at risk for VTE and that 50% of all patients at risk for
VTE received anticoagulants, anticoagulation prophylaxis was associated with a 12-fold
increase in hospital-acquired FPE (OR: 12.0; 95% CI, 1.6-92) [22].
An autopsy study by Lindblad and colleagues [23] from Malmo, Sweden corrobo-
rated the Goldhaber study. From a population of 31,238 post-operative patients from
the 1980s, it found that 27/30 patients with autopsy-proven FPE had received post-op
prophylactic anticoagulants. The authors did not report the proportion of ‘high VTE
risk’ surgical patients in their hospital receiving anticoagulant prophylaxis. To provide
an approximation of the degree of increased risk of FPE related to anticoagulant pro-
phylaxis in this autopsy study from a defined clinical population, we can conservatively
assume that all Malmo surgical patients had ‘high VTE risk’ and again use Goldhaber’s
estimate that about 50% of those at risk received anticoagulant prophylaxis [14]. This
translates to about 15,619 patients with anticoagulants and the same number without.
Compared with patients not receiving anticoagulant prophylaxis, the Lindblad autopsy
data show the estimated FPE rate in anticoagulated patients is nine-fold higher (OR:
9.0; 95% CI, 2.7-29.6).
Since many Malmo surgical patients would have been at ‘low VTE risk’ and fewer
than 50% of those at ‘high VTE risk’ may have received anticoagulants in the 1980s,
the FPE rate associated with anticoagulant prophylaxis could well have been consider-
ably higher. Combining the FPE data from Goldhaber and Lindblad yields a very con-
servative estimated increased FPE risk associated with anticoagulant prophylaxis of
9.75 fold (OR, 9.75; 95% CI, 3.5 - 27.3). Combining these studies, 35/43 cases can be
attributed to ‘rebound hypercoagulation’ (i.e., 39/43 FPE patients had received anticoa-
gulation prophylaxis versus 4/43 with no anticoagulation: 39 - 4 = 35).
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tion and fibrinolytic systems. Post-operative prophylactic anticoagulants significantly
mitigate the stimulation of these systems. However, following the discontinuation of
prophylactic anticoagulants, a second wave of activation of markers of the coagulation
and fibrinolytic systems continues for up to 35 days after surgery (e.g., plasma TAT
and D-dimer [24]). Cundiff has suggested that ‘rebound hypercoagulation’ after stop-
ping anticoagulants causing restimulation of coagulation and fibrinolysis may account
for this marked increase in FPE risk associated with anticoagulant treatment [25] and
prophylaxis [26]. Given that at least 12 million medical and surgical patients worldwide
receive prophylactic anticoagulants per year [14,15], an estimated 5,000 to 40,000 peo-
ple per year die of ‘rebound hypercoagulation’ (i.e., 12,000,000 (hospitalized people/
year with anticoagulant prophylaxis) × 35/28,419 (excess risk for fatal PE per Goldha-
ber and Lindblad studies) = 14,779; 95% CI, 5,305 - 41,381).
While in the Goldhaber study 11/13 (85%) of FPE cases were in medical ward
patients and only 2/13 were in surgical patients, the larger Lindblad study included
anticoagulation prophylaxis data only on surgical patients. In the Lindblad study, 113
patients had PE as the principal cause of death, of which 83/113 (73%) were medical
patients and 30/113 were post-operative. Lindblad did not report the anticoagulant
prophylaxis status of the medical FPE patients. Since anticoagulated medical patients
are about 50 times more likely than surgical patients to have FPE (Tables 1 and 2), the
actual number of anticoagulated patients with FPE due to ‘rebound hypercoagulation’
is likely much higher than derived from combining these two autopsy studies because
of the disproportionately high number of surgical patients.
Marked reduction in FPE risk over time unrelated to anticoagulants
In the 1960s and 1970s, FPE in trials of post-op surgical patients without anticoagulant
prophylaxis averaged 0.99% while FPE rates in anticoagulated patients averaged 0.31%
(Table 3). Since about 1980, prompt ambulation of post-op patients and other non-
drug VTE prophylaxis measures (e.g., mechanical prophylaxis ofl o w e rl i m b s )h a v e
been widely implemented. Recent observational studies and RCTs of surgical patients
at VTE risk both not receiving and receiving prophylactic anticoagulants show a some-
what reduced VTE incidence and a markedly lower FPE frequency than seen in studies
from the 1960s and 1970s (see Tables 2 and 4).
Table 1 FPE incidence VTE observational studies and RCTs in medical patients from the
1980s to 2000s
Author FPE incidence no anti-coagulation FPE incidence with anti-coagulation
Mahé [89] 17/1,244 10/1,230
Alikhan [87] 467/9,491 431/9,349
Cohen [90] 5/414 0/425
Testroote [91] 0/454 0/442
Bergmann [92] 17/1,244 10/1,230
Bergmann [93] NA 2/439
Fraisse [94] 0/114 1/109
Turpie [95] 0/650 0/635
506/13,611 (3.7%) 453/13,859 (3.3%)
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1980s to 2000s
Population of surgical patients) Author FPE incidence no
anti-coagulation
FPE incidence with
anti-coagulation
general surgical Kosir [96] 0/70 0/38
general surgical Kosir [97] 1/68 0/68
general surgical Rasmussen [98] 1/405 0/388
total general surgical 2/543 (0.37%) 0/494 (0%)
orthopedic surgical Sasaki [99] 0/38 0/38
orthopedic surgical Bi [100] 0/35 0/35
orthopedic surgical Goel [101] 0/111 0/127
orthopedic surgical Agarwal [102] 0/131 0/166
orthopedic surgical Eriksson [103] NA 0/1,587
orthopedic surgical Eriksson [104] NA 0/1,464
orthopedic surgical Heit [105] NA 1/594
orthopedic surgical Eriksson [106] NA 0/133
orthopedic surgical Francis [107] NA 0/2,285
orthopedic surgical Eriksson [108] NA 1/2,056
orthopedic surgical Turpie [109] NA 5/7,211
orthopedic surgical Ramos [110] 0/262 0/267
orthopedic surgical Ginsberg [111] NA 1/1,896
orthopedic surgical Agnelli [112] NA 0/507
orthopedic surgical Turpie [113] NA 0/613
orthopedic surgical Colwell [114] NA 0/1,838
orthopedic surgical Eriksson [115] NA 1/1,872
orthopedic surgical Eriksson [116] NA 2/2,835
orthopedic surgical Eriksson [117] NA 1/2,788
orthopedic surgical Colwell [118] NA 3/2,299
total orthopedic surgical 0/577 (0%) 15/29,291 (0.051%)
unspecified surgical Rosenzweig [119] 0/4,705 NA
unspecified surgical Nurmohamed [120] NA 11/8,172
total unspecified surgical 0/4,705 (0%) 11/8,172 (0.135%)
surgical totals 2/5,825 (0.034%) 26/37,957 (0.068%)
Table 3 FPE incidence in surgical patients in the 1960s and 1970s
Population (medical, surgical,
etc.)
Author FPE incidence no anti-
coagulation
FPE incidence with anti-
coagulation
general surgical Clagett
[27]
48/5,547 (0.87%) 19/6,845 (0.28%)
orthopedic surgical Collins
[29]
15/801 (1.87%) 5/826 (0.61%)
total surgical 63/6,348 (0.99%) 24/7,671 (0.31%)
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prophylaxis of patients at high risk for VTE relies, do not pertain to ‘high VTE risk’
hospitalized patients in the 21
st century for eight reasons:
1. Very few of the subjects in the earlier studies received mechanical prophylaxis
such as graded compression stockings, which are now the standard of care and
have been shown in a meta-analysis of trials from the 1960s and 1970s to reduce
VTE significantly more than low-dose heparin (VTE with low dose heparin: 23/173
(13.3%) versus VTE with compression stockings: 14/190 (6.8%), P = 0.04) [27]. In
an RCT published in 1996 of VTE prophylaxis for neurosurgical patients compar-
ing graded compression stockings alone with graded compression stockings plus
LMWH, the LMWH plus stockings group had a significantly higher overall mortal-
ity (22/241 versus 10/244: p = 0.026) [28].
2. Post-operative and medical patients today become ambulatory much earlier than
in the 1960s and 1970s, reducing FPE risk.
3. Probably because of #1 and #2 above, rates of FPE in ‘high VTE risk’ surgical
patients without anticoagulant prophylaxis from the 1960s and 1970s are over
40 times the rates reported from more recent studies (63/6,348 (0.99%)) [27,29]
(Table 3) versus 5/21,444 (0.023%) from Lindblad’s post-op autopsy study (Table 4
[23]) combined with a representative sampling of surgical anticoagulation prophy-
laxis RCTs (Table 2).
4. In studies from 1980 to 2010, the rate of FPE in surgical patients receiving antic-
oagulant prophylaxis (53/53,576 (0.10%), combining Table 4 Lindblad with Table 2
totals) is over four times higher than the FPE rate of recent unanticoagulated surgi-
cal patients (5/21,444 (0.023%), Table 4 Lindblad and Table 2 totals). This suggests
that anticoagulant prophylaxis may now increase FPE.
5. Very few of the recent or old VTE prophylaxis RCTs (anticoagulant versus none)
included FPE cases occurring after discontinuation of the anticoagulant and dis-
charge from hospital, thereby missing those dying of ‘rebound hypercoagulation’.I n
the Goldhaber chart study above, 45% of hospital-acquired VTE cases occurred in
the 30 days after hospital discharge. On the basis of the Goldhaber and Lindblad
studies [21,23] that included FPE occurring at least one month after stopping pro-
phylactic anticoagulation, about 80% of FPE cases documented at autopsy in recent
years appear to be due to ‘rebound hypercoagulability’ (i.e., 35/43, see above).
6. Owing to the high rate of FPE in unanticoagulated ‘high VTE risk’ patients in
the 1960s and 1970s (0.99%) and even in those then receiving anticoagulant pro-
phylaxis (0.31%), ‘rebound hypercoagulability’ related FPE in that previous era
would have been missed. Relative to the FPE rates in the 1960s and 1970s, it
Table 4 FPE incidence in autopsy studies from the 1980s to 1990s
Population (medical,
surgical, etc.)
Author FPE incidence no anti-
coagulation
FPE incidence with anti-
coagulation
surgical Lindblad [23] 3/15,619 27/15,619
medical and surgical Goldhaber*
[21]
1/12,800 12/12,800
4/28,419 (0.014%) 39/28,419 (0.13%)
* 8/13 patients had autopsy confirmation
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(35/28,400), Table 4, or about 1/800 patients). However, since 1980 with markedly
lower FPE rates in post-op patients generally (i.e., 0.034% without anticoagulation
and 0.068% with anticoagulant prophylaxis, Table 2), we should be very concerned
about missing a 0.12% estimated incidence of ‘rebound hypercoagulation’-related
FPE.
7. The FPE rates in medical patients in the 1960s and 1970s are not documented in
anticoagulation versus no anticoagulation RCTs. From 1980 to 2010, medical
patients have had up to 100 times the FPE rate of surgical patients and that rate is
not reduced significantly by anticoagulant prophylaxis (i.e., no anticoagulation: 3.7%
versus anticoagulated: 3.3%, Table 1). However, these medical patient trials record
FPE only while patients are on anticoagulants and also potentially miss cases of
FPE due to ‘rebound hypercoagulation’.
8. A high proportion of patients with autopsy-verified FPE had underlying terminal
illnesses (e.g., FPE rates in two large autopsy series: 95% (169/178 [30]) and 96.5%
(1,867/1,934 [31])). Since surgeons try to avoid performing elective operations on
terminally ill people and medical services frequently care for terminally ill patients,
the low FPE rate in surgical RCTs and high rate in acute medical patients makes
sense. Out of the total group of ‘high VTE risk’ patients, those undergoing pro-
longed bed rests due to cancer, heart failure, or other organ failure may be particu-
larly prone to FPE despite being on prophylactic anticoagulants and, additionally,
due to ‘rebound hypercoagulation’.
Given (1) the incidence of major and fatal bleeding from anticoagulants for prophy-
laxis and treatment of VTE, (2) the efficacy data for both that have been called into
question, and (3) the evidence for previously unrecognized and largely uncounted
deaths from ‘rebound hypercoagulability’; reconsideration of the evidence-basis of
anticoagulants for treatment and prophylaxis of VTE is in order.
Diet and VTE
Although therapeutic diets are widely suggested for prophylaxis and treatment of arter-
ial cardiovascular disease, healthy nutrition as an approach to prophylaxis and treat-
ment of VTE has never been officially recommended. Acting U.S. Surgeon General Dr.
Steven Gaston noted in his call to action to prevent VTE that the “Longitudinal Inves-
tigation of Thromboembolism Etiology (LITE) “ s t u d y[ 3 2 ]f o u n dad i e tw i t hm o r e
fruits, vegetables, and fish, and less red and processed meat to be associated with a
lower VTE incidence. He suggested further studies on the impact of diet and other
lifestyle changes regarding VTE [33].
Data about the relationship of diet to VTE risk come from:-
￿ historical observations about the incidence of FPE under wartime conditions,
including food rationing, in early 20
th century European cities;
￿ prospective observational studies of diet and lifestyle factors associated with VTE;
￿ case-control studies of VTE patients looking at lipid profiles, inflammation mar-
kers, and coagulation variables;
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markers, and coagulation variables.
Historical data
In Norway from 1940 to 1944, intake of meat, whole milk, cream, margarine, cheese,
eggs, and fruit decreased while people increased their intake of fish, cod liver oil,
skimmed milk, whole grain bread, potatoes, and fresh vegetables. The rate of post-
operative VTE decreased markedly during the Second World War in Norway followed
by a marked increase after the war [34].
During the Second World War, people in Norway, Sweden, Switzerland, Germany,
Finland, and Denmark had significantly reduced intake of food from animal sources.
However, only Denmark showed no decrease in vascular disease mortality. In Denmark
alone, there was no significant reduction in consumption of dairy fats and eggs [35].
The autopsy incidence of FPE over time in Heidelberg, Germany showed a clear rela-
tionship between pulmonary embolism and wartime conditions. The lowest incidence
of FPE, expressed as a percentage of all hospitalized patients, was registered during the
post-Second World War years with a relative and absolute minimum between 1945
and 1949. The 1947 value (0.04%) was lower than 1932 (0.45%) or 1955 (0.38%) [36]
(Fig. 1).
In Vienna after the First World War, FPE accounted for less than 0.5% of deaths ver-
sus 2.5% in the early 1930s. Again, in the late 1940s, incidence of FPE at autopsy was
<1% versus almost 8% by the early 1970s [30] (Fig. 2).
These historical studies have limitations but suggest that the high-complex-carbohy-
drate, low-fat diet associated with war-time food rationing and perhaps increased exer-
cise may have markedly reduced the tendency to form thrombi and/or lessened the
consequences of those that do form. Judging from the autopsy data, the effects of
these lifestyle influences on VTE risk had a rapid onset and offset, and wartime condi-
tions afforded substantial protection against VTE, especially FPE.
Figure 1 Fatal PE from 1915 to 1964 in Heidelberg, Germany [36]. Absolute numbers of patients with
autopsy-proven FPE in black, and percentage of in hospital patient deaths related on autopsy to PE in
white. Reproduced from Linder et al. [88].
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In the “Longitudinal Investigation of Thromboembolism Etiology (LITE) “ prospective
study, hazard ratios (95% CIs) of VTE incidence across quintiles of fruit and vegetable
intake were: 1.0 (reference: lowest quintile), 0.73 (0.48 to 1.11), 0.57 (0.37 to 0.90), 0.47
(0.29 to 0.77), and 0.59 (0.36 to 0.99) with Ptrend = 0.03 [32]. The fruit and vegetable
intake in the lowest quintile, 2.0 servings per day, was far less than recommended by
the United States Center for Disease Control (i.e. >5 servings per day for most people)
[37]. The highest quintile averaged 6.7 servings per day. Meat intake was a predictor of
VTE risk in LITE (HRs of VTE across quintiles of red and processed meat intake–1.0
(lowest quintile), 1.24 (0.78 to 1.98), 1.21 (0.74 to 1.98), 1.09 (0.64 to 1.87), and 2.01
(1.15 to 3.53) with the Ptrend = 0.02 [32]). Since fruit/vegetable intake in LITE corre-
lated negatively with meat intake (r = - 0.28), the two most influential dietary variables
may have acted synergistically on VTE risk.
In contrast, the Iowa Women’s Health Study (IWHS) [38], to date the only other
large prospective study of diet related to VTE risk, found no associations of VTE risk
with intake of fruits/vegetables, meat, fish, or other foods. It also found no significant
associations with dietary patterns or individual nutrients. The IWHS found an associa-
tion of daily alcohol consumption with lowered VTE risk, whereas LITE only affirmed
that adjusting for alcohol consumption did not diminish the strength of the correla-
tions between diet and VTE [32]. The following differences between the LITE and
IWHS studies may account for the discrepancies:
￿ Only women were surveyed in the IWHS (99% white women); the LITE study
included relatively fewer women (55%) and more non-whites (27%).
Figure 2 Vienna, Austria percentages of autopsies with fatal PE (Quoted by Nielsen from Sigg
[30,36]).
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tionnaire (FFQ), considered more precise than the self-administered IWHS ques-
tionnaire [32].
￿ W h i l et h eI W H SF F Qa s s e s s m e n tw a sd o n eo n l yo n c ea n dr e l a t e dt ot h es u b s e -
quent 19 year (mean 13 year) follow-up for VTE incidence, the LITE FFQ assess-
ment was done twice, six years apart (r ranged from 0.49 to 0.56 between the two
assessments). This allowed the LITE diet assessment to be based on a cumulative
average dietary intake. The designers of the FFQs used in both studies found that
using the cumulative averages, in general, yielded stronger associations than utiliz-
ing either baseline diet or the most recent diet alone [39].
Therefore, the LITE study findings relating fruit and vegetable intake to reduced
VTE risk and meat intake to increased VTE risk have more scientific validity than the
IWHS finding of no dietary factor influences on VTE. The LITE findings are also
consistent with the historical observations (above).
VTE risk related to lipids, inflammation, and hemostatic parameters
A meta-analysis of VTE case-control studies found that VTE patients had significantly
lower HDL cholesterol levels and higher triglycerides but no differences in total choles-
terol or LDL-cholesterol [40]. Prospective studies of associations between lipid levels
and VTE risk are conflicting but possibly suggest that VTE risk is reduced when
serum levels of HDL cholesterol are higher and triglyceride lower [41].
In LITE, VTE was not correlated with C-reactive protein or white cell count [42].
However, LITE did not differentiate between idiopathic versus secondary VTE cases.
Luxembourg and colleagues reported a case-control study comparing idiopathic VTE
with risk-associated VTE patients (post-op, etc.) and controls. Idiopathic VTE patients
had significantly higher levels of high-sensitivity C-reactive protein (hs-CRP) than sec-
ondary VTE patients (mean 1.8 versus 1.5, P = 0.05), who had significantly higher
levels than controls (mean 1.5 versus 1.2, P = 0.02) [43].
Case-control and prospective studies show correlations of VTE with serum levels of
factor VIII [43-47]. The VTE case control study by Luxembourg and colleagues found
significantly higher fibrinogen levels in patients with idiopathic VTE than those with
risk-associated VTE (median: 331 versus 299 mg/dl, p = 0.004) [43]. Controls had
levels similar to risk-associated VTE patients (median: 302 mg/dl). In LITE, factor VIII
levels and von Willebrand factor levels correlated significantly with VTE (P for trend
in quartiles <0.0001 for both) but fibrinogen levels did not. LITE did not assess platelet
aggregation or indices of fibrinolysis.
Alcohol and VTE
T h eI o w aW o m e n ’s Health Study reported that daily alcohol imbibers suffered fewer
episodes of VTE. This finding is questionable, since a single assessment of alcohol
intake was related to VTE incidence over the ensuing 19 years [38]. The LITE study
found that alcohol consumption neither increased nor decreased VTE risk [32].
There is no other prospective epidemiological evidence linking alcohol use with
either increased or decreased risk of VTE.
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In LITE, fish intake was deemed protective against VTE on the basis of a comparison
of VTE incidence between the first quintile of fish consumption and the sum of the
four subsequent quintiles: 1.0 (first quintile) 0.58 (0.37-0.90) 0.60 (0.39-0.92) 0.55
(0.35-0.88) 0.70 (0.44-1.10), Ptrend= 0.30). This post hoc comparison is dubious
because fish consumption correlated positively with intake of fruits/vegetables (r =
0.27, P < 0.001) [32]. The correlation between fish and meat consumption was not
reported. In an analysis of the Diabetes Control and Complications Trial database by
Cundiff and colleagues [48], long chain omega-3 fatty acid intake (a marker for fish
consumption) correlated inversely with percentage of calories from saturated fatty
acids (r = -0.21, P < 0.0001), and directly with dietary fiber intake (g/1,000 kcal) (r =
0.20, P < 0.0001), suggesting that fish eating is correlated with a more plant-based than
animal-based diet. In a Greek study of diet in people with and without acute coronary
syndromes [49], fish intake was associated with consumption of:
￿ red meat - inversely related in patient and control groups (P< 0.001 for both);
￿ vegetables - directly correlated (P< 0.001 for both);
￿ fruit - directly correlated (P< 0.001 for both); and
￿ legumes - directly correlated (P< 0.001 for both).
B e c a u s ef i s hi n t a k ei sc o n f o u n d e dw i t ho ther healthy dietary choices in the LITE
database and other studies, fish consumption does not appear to be an independent
protective factor for VTE. The possibility may nevertheless merit further study taking
account of the confounding variables.
Diets to consider for lowering VTE risk
Low VTE risk diets (i.e., high in fruits and vegetables and low in red and processed
meats) to consider as the experimental arm of non-inferiority randomized trials evalu-
ating standard anticoagulants for prophylaxis and treatment of VTE are as follows:
American Heart Association (AHA) step 1 and step 2 diets
AHA step 1 and step 2 diets recommend plenty of fruits and vegetables, lean meat and
two servings of fish per week [50]. A meta-analysis of randomized trials of these diets
versus regular diets (27 trials with more than 30,000 patient years of follow-up) shows
no significant reduction of overall mortality (RR: 0.98, 95% CI 0.86 to 1.12), or cardio-
vascular disease mortality (RR: 0.91, 95% CI 0.77 to 1.07) [51,52].
There is no evidence that the AHA step 1 or step 2 diets would reduce VTE risk any
more than overall cardiovascular risk, so they would not be good low VTE risk diet
candidates.
Mediterranean diet (MD)
While the MD does not significantly benefit serum lipids, blood pressure, or body mass
index, it reduced overall cardiovascular disease risk by 70% in the “Lyon Diet Heart
Study “ [53].
Studies in Table 5 suggest that the MD benefits markers of coagulation, inflamma-
tion, and cardiovascular disease risk.
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Epidemiological studies show that people consuming vegetarian diets (lacto-ovo, lacto,
ovo, or not otherwise specified (NOS)) and vegan diets (no meat, dairy, or eggs) have
lower overall vascular disease incidence than omnivores [54-58].
A lacto-ovo vegetarian diet contains plenty of fruits and vegetables and no meat, lar-
gely conforming to the LITE prospective data regarding a low VTE risk diet [32]. How-
ever, the lack of decreased vascular disease risk in Denmark during and after the
Second World War (see above) [35] might be considered a point in favor of a vegan
diet.
Tables 6, 7, and 8 show representative studies of vegetarian and vegan diets related
to VTE risk and inflammatory, lipid, and hematological markers, respectively, demon-
strating trends favorable to these diets.
A study from Rotterdam assessed the relationship of dietary fat and fiber with coagu-
lation factor VII in 3,007 elderly men and women subjects. Total fat and saturated fat
Table 5 MD studies of serum markers of inflammation and coagulation
Author Study
Design
Population Exposure
variable
Outcome variable Results
Esposito [76] RCT Metabolic
syndrome
patients
MD 1. Nutrient intake
2. endothelial function
3. lipid and glucose
parameters
4. insulin sensitivity
5. hs-CRP
6. IL-6
7. IL-7
8. IL-18
With MD
1. hs-CRP decreased
(P = 0.01)
2. IL6 decreased
3. (P = 0.01)
4. Endothelial function
improved (P < 0.001)
5. lipid and glucose
parameters improved
(P < 0.001)
6. decreased insulin
resistance (P < 0.001)
Mezzano [77] RCT Healthy
volunteers
MD versus high
fat diet
Fat content
Fibrinogen
factor VIIc
factor VIIIc
protein S
Fat content
- MD: 27.3%
- HFD: 39.9%
With MD
Fibrinogen reduced
(P = 0.03)
factor VIIc reduced
(P = 0.034)
factor VIIIc reduced
(P = 0.0057)
protein S increased
(P = 0.013)
Antonopoulou
[75]
Observa-
tional
Healthy
volunteers
and type 2
DM patients
MD platelet aggregation in
response to platelet
aggregating factor or
thrombin
Platelet activity
reduced in both
groups
Chrysohoou
[74]
Observa-
tional
People in
Greece
Adherence to MD
comparing the
highest and
lowest tertile
CRP
IL-6
Homocysteine
WBCs
highest tertile
participants averaged
- 20% lower CRP levels
(P = 0.015)
- 17% lower
interleukin-6 levels
(P = 0.025)
- 15% lower
homocysteine levels
(P = 0.031)
- 14% lower white
blood cell counts
(P = 0.001)
- 6% lower fibrinogen
levels (P = 0.025)
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inversely associated with factor VIIc in both men and women [59].
Mediterranean, vegetarian or vegan diets could all be reasonable choices for the
experimental arm of non-inferiority trials with anticoagulants for prophylaxis and
treatment of VTE. Given the challenges to patients in changing diets and the likelihood
that RCTs would show that anticoagulation prophylaxis and treatment for VTE are
themselves ineffective as suggested in the background section above, RCTs of VTE
patients should allow considerable flexibility in the diet interventions so that they are
not burdensome.
Vitamin K intake and VTE risk
Studies on vitamin K and VTE risk or coagulation profiles are very limited, because
there is no established role of vitamin K supplementation except in people who are
deficient in vitamin K. Based on the hypothesis that vitamin K supplementation may
protect against atherosclerosis, a placebo-controlled randomized trial evaluated the
Table 6 Studies of vegetarian diets and serum markers of inflammation
Author Study
Design
Population Exposure
variable
Outcome
variable
Results
Mezzano [70] Case-
control
52 Chilean subjects Lacto or lacto-ovo
Vegetarians v.
Omnivores
CRP NS
Chen [65] Case-
control
198 healthy Taiwanese
subjects
Vegetarians (NOS)
v. Omnivores
CRP NS
Harvinder
[121]
Case-
control
47 USA subjects with
CAD or CAD risk factors
Vegans v.
Omnivores
CRP Vegans had significantly
lower levels of CRP
Kjeldsen-
Kragh [64]
Case-
control
53 Rheumatoid arthritis
patients
Lacto vegetarians
v. Omnivores
WBC
count
Lacto vegetarians had
significantly lower WBCs
Kjeldsen-
Kragh [72]
Case-
control
Rheumatoid arthritis
patients
Vegetarians (NOS)
v. Omnivores
WBC
count
Vegetarians had
significantly lower WBCs
Nazarewicz
[62]
Case-
control
22 vegetarian and 19
omnivore Pols
Vegetarians (NOS)
v. Omnivores
WBC
count
Vegetarians had
significantly lower WBCs
Pongstaporn
[122]
Case-
control
178 vegetarian and 58
omnivore Thais
Vegetarians (NOS)
v. Omnivores
WBC
count
Vegetarians had
significantly lower WBCs
Arm-strong
[63]
Case-
control
431 vegetarian and 131
omnivore Seventh-day
Adventists
Vegetarians (NOS)
v. Omnivores
WBC
count
Vegetarian men but not
women had significantly
lower WBCs
Haddad [68] Case-
control
25 vegan and 20
omnivore Californians
Vegans v.
Omnivores
WBC
count
Vegans had significantly
lower WBCs
Tungtrong-
chitr [67]
Case-
control
132 vegetarians and 47
omnivores from Thailand
Vegetarians (NOS)
v. Omnivores
WBC
count
NS
Malter [66] Case-
control
German male
vegetarians and
omnivores
Vegetarians (NOS)
v. Omnivores
WBC
count
NS
Table 7 Studies of vegetarian diets and serum lipid markers
Author Study
Design
Population Exposure
variable
Outcome
variable
Results
Li [73] Case-
control
139 healthy male
subjects aged 20-55
Melbourne
Vegetarians
(NOS) v.
Omnivores
ratios of
triglycerides/HDL-
cholesterol
Vegetarians had lower ratios
of triglycerides/HDL-
cholesterol
Chen
[65]
Case-
control
198 healthy Taiwanese
subjects
Vegetarians
(NOS) v.
Omnivores
levels of total
cholesterol and
LDL-C
Vegetarians had lower levels
of total cholesterol and
LDL-C
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fibrinolytic activity in postmenopausal women. No effect was seen on inflammatory or
fibrinolytic markers and lipid markers worsened (i.e., increased triacylglycerols and
decreased HDL-C) [60]. A systematic review of RCTs of vitamin K supplementation
for preventing bone loss and fractures yielded 13 trials. None of the trials reported an
increase in VTE or other adverse reactions [61]. Vitamin K status does not seem to be
a significant factor in VTE risk.
Effects of diet in relation to the VCHH
The simplest and most plausible mechanistic link between diet and DVT/VTE is
through other aspects of lifestyle: people who eat unhealthy diets are likely to exercise
less and remain sedentary for longer than those who eat healthy diets, exposing them
to a greater risk of prolonged non-pulsatile venous blood flow and consequent valve
pocket hypoxemia. However, subtler links between diet and venous thrombogenesis
can be inferred from the VCHH.
Compared with subjects taking omnivorous diets, a non-vegan vegetarian diet is
associated with a lower neutrophil count in some studies [62-64] though not all
[65-67]. Subjects on vegan diets consistently show lower neutrophil counts [68,69].
Studies have provided mixed findings regarding platelet counts and function in vege-
tarians and vegans [62,68,70-73].
A reduced number of neutrophils would tend to attenuate the invasion of a hypoxi-
cally injured (necrotic) valve cusp endothelium by leukocytes, which according to the
VCHH would militate against the events initiating thrombogenesis. This suggests a
mechanism by which vegan diets could reduce the risk of VTE.
In that the MD has been found to decrease the white blood cell count [74], reduce
platelet activity [75], decrease markers of inflammation [76], improve endothelial func-
tion [76], and lower factor VII and VIII levels [77]; it may be consistent with reduced
neutrophil margination and sequestration on a hypoxically damaged valve cusp, asso-
ciated with elevation of EDRF and non-elevation of p38 MAPK and thus with a
decreased risk for venous thrombogenesis (see chapter 12 in [2]) [78].
Table 8 Studies of vegetarian diets and serum markers of coagulation
Author Study
Design
Population Exposure
variable
Outcome variable Results
Li [73] Case-
control
139 healthy
male subjects
aged 20-55 in
Melbourne
Vegetarians
(NOS) v.
Omnivores
factor VII activity Lacto-ovo vegetarians had
significantly lower plasma
factor VII activity
Mezzano
[70]
Case-
control
52 Chilean
subjects
Lacto or
lacto-ovo
Vegetarians
v.
Omnivores
PT, fibrinogen, factor Vc,
factor VIIc, factor VIIIc,
antithrombin III, protein S,
plasminogen, protein C
Lacto-ovo vegetarians had
significantly lower levels of
fibrinogen, factor Vc, factor
VIIc, factor VIIIc, antithrombin
III, protein S, plasminogen,
prothrombin, protein C
Pan [123] Case-
control
203 healthy
Taiwanese age
<30
60
vegetarians
and 143
omnivores
PT, APTT, fibrinogen, factor
VIIc, factor VIIIc,
antithrombin III,
plasminogen,
Vegetarian men did not differ
from omnivore men.
Women: factor VIIIc higher and
APTT shorter in vegetarian
women versus omnivore
women
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proposed
Given the risks of anticoagulation for VTE and new data concerning the current
reduced risk of hospital-acquired VTE, researchers should consider non-inferiority ran-
domized trials to test the efficacy and safety of anticoagulants for prophylaxis of VTE
for medical and surgical patients. Likewise, given the lack of RCT evidence of efficacy
of anticoagulant treatment of VTE, a non-inferiority RCT would be in order to test the
efficacy and safety of anticoagulants for treatment of VTE.
To enlist researchers and patients in these proposed trials, the rationale must be
clearly explained and appropriate experimental arms determined. Experimental arm
options include using placebos or non-steroidal anti-inflammatory drugs (NSAIDs).
However, a Cochrane review of anticoagulation treatment for VTE concluded that:
“The use of anticoagulants is widely accepted in clinical practice, so a further RCT
comparing anticoagulants to placebo could not ethically be carried out “ [20]. An
NSAID would have the advantage of being a weak antithrombotic with less bleeding
risk than anticoagulants; however, epidemiological evidence suggests that NSAIDs may
increase the risk of VTE [79].
Given the relationship between diet and VTE noted above, low VTE risk diet inter-
ventions should be explored as possible experimental arms in randomized non-infer-
iority trials testing the efficacy and safety of anticoagulants for prophylaxis and
treatment of VTE.
If such trials yield positive results, they may be especially useful in developing coun-
tries, where there is a significant and increasing risk of DVT and VTE in medically ill
patients but only a minority receives anticoagulant prophylaxis [80,81]. Practitioners in
these countries recognize the economic and other difficulties of providing anticoagulants
for all patients for whom they are not contraindicated and recommend careful risk stra-
tification and education [80,82]. Education could include dietary advice. Interestingly,
there is strong evidence that oral contraceptives currently used in developing countries
entail a statistically significant risk of VTE, but only among women with high body mass
indices [83,84]; again, this could indicate that dietary prophylaxis would be beneficial.
Statistical considerations in designing non-inferiority trials
To provide convincing evidence for a change in standard-of-care treatment/prophylaxis
for VTE, from anticoagulants to a lower-risk alternative like low-VTE-risk diet, a defi-
nitive clinical trial would have to accomplish two goals simultaneously:
1. demonstrate that the diet is significantly safer than anticoagulants with respect
to hemorrhage, and
2. demonstrate that the diet is non-inferior to anticoagulants with respect to the
prevention or amelioration of major complications of VTE.
This requires a safety/efficacy trial with two co-primary endpoints...
1. a primary safety endpoint – an undesired hemorrhagic event, and
2. a primary efficacy endpoint –an undesired thromboembolic event, such as fatal
or non-fatal PE, recurrent symptomatic PE, or symptomatic DVT.
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endpoints determine the sample size needed for the study – there must be a sufficient
number of each endpoint observed, so that the study will have sufficient statistical
power to yield simultaneous significant outcomes in testing each of the two co-primary
study hypotheses – better safety and non-inferior efficacy for the low VTE risk diet,
relative to the anticoagulants.
So the co-primary safety and efficacy endpoints must be consequential enough to
provide convincing motivation to change medical practice, and frequent enough to
yield a sufficiently powered study with a reasonable sample size. Of course, a set of
secondary safety and efficacy endpoints would also be monitored and analyzed. For
any given choice of endpoints, the study design would take the form of a prospective,
parallel, randomized, active-comparator, unblinded interventional clinical trial.
The occurrence or non-occurrence of each safety and efficacy endpoint within the
stated follow-up interval will be recorded. Potential confounders (subject age, gender,
medical history, type and severity illness, type and duration of surgery, etc.) will also
be recorded. These will be tested for balance between the two treatment groups by
Student’s t or chi-square tests. Variables found to be significantly unbalanced between
groups (p ≤ 0.1) will be adjusted for in the analyses, as described below.
Statistical analysis will consist of a comparison, between treatment groups, of the
fraction of subjects experiencing each of the two co-primary endpoints.
If no adjustment for potential confounders is necessary, the rates will be compared
by cross-tabulating, for each endpoint, the treatment group by the occurrence/non-
occurrence of the endpoint in a 2-by-2 table, and determining the “raw “ (unadjusted)
odds ratio for the occurrence of the event, for the diet, relative to the anticoagulant,
along with its upper 1-sided 95% confidence limit. If adjustment for potential confoun-
ders is necessary, the odds ratio and its upper 1-sided 95% confidence limit will be
obtained by multivariate logistic regression, where the occurrence of the endpoint is
the dependent variable, the treatment group is the main independent variable, and the
confounders are covariates. Alternatively, a propensity score can be calculated for each
subject, incorporating all significant confounders. This score can be used in place of
the individual confounders in the logistic regression.
Regardless of which way the odds ratios are calculated, significantly better safety for
the diet will be inferred if the confidence interval around the odds ratio (diet/anticoa-
gulant) for the primary safety endpoint lies entirely below the value of 1. Non-inferior
efficacy for the diet will be inferred if the confidence interval around the odds ratio
(diet/anticoagulant) for the primary efficacy endpoint lies entirely below the value 1.5,
corresponding to an “allowable non-inferiority tolerance “ of 50%.
The sample size required for 80% power to infer improved safety and non-inferior
efficacy simultaneously will depend on the expected incidence rates of the primary
safety and efficacy endpoints, the expected amount of improvement in safety for diet
relative to anticoagulants, and the expected difference in efficacy (if any) between the
two treatments.
While the FPE rate may appear to be the logical primary efficacy endpoint for RCTs
comparing standard anticoagulant prophylaxis and treatment with a low VTE risk diet,
FPE data are unreliable for several reasons:
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rely on clinical diagnoses of FPE.
￿ Clinician FPE diagnoses correlate very poorly with autopsy diagnoses of FPE in
both directions (i.e., more than 50% false positives and more than 50% false nega-
tives [85]).
￿ At autopsy, the pathologist has to decide if the PE was the fatal event or just a
contributing condition. This is quite subjective.
◦ Studies in the literature report postmortem exams inconsistently (i.e., classifi-
cations such as “incidental,”“ contributing to death” or “fatal” PE vary).
◦ In a meta-analysis of cohort studies with a low proportion of deaths investi-
gated with autopsies, the overall mortality of patients undergoing elective hip
and knee replacement was about 2 1/2 times the rate of FPE (total mortality:
0.93% versus FPE rate: 0.36%) with most of the non FPE deaths from heart fail-
ure or myocardial infarction [86]. FPE very frequently occurs in those with
underlying severe cardiovascular disease, so FPE could not be ruled out without
autopsies on all cardiovascular deaths.
￿ Using FPE at the sole primary endpoint takes no account of deaths from anticoa-
gulant-induced bleeding.
Consequently, ‘total mortality’ should be the primary efficacy endpoint, because it is
more reliable, consequential, and frequent than FPE. Screening for asymptomatic PE or
DVT as efficacy endpoints would not be necessary, because they correlate poorly with
FPE and total mortality.
The most consequential and frequent primary safety endpoint for RCTs would be
‘total bleeding’. This includes minor bleeding, wound hematomas, and major bleeding.
Secondary endpoints should be FPE, symptomatic PE, symptomatic DVT, fatal bleed-
ing, and major bleeding.
Example–RCT for VTE prophylaxis of hospitalized medical inpatients: Low VTE risk diet
versus standard anticoagulants
For a hypothetical example anticoagulant prophylaxis RCTs, consider acutely ill
patients admitted to hospital medical wards. American Association of Chest Physician
(ACCP) Guidelines suggest that such patients receive LMWH, low dose heparin, or
fondaparinux as VTE prophylaxis
11. We may use total bleeding (minor, major, and
fatal bleeding) as the primary safety endpoint. A recent Cochrane Review of prophylac-
tic anticoagulation for medical patients found that bleeding occurred in 117/2,405
(4.9%) of anticoagulated patients and 62/2,404 (2.6%) of untreated patients [87].
Subjects would be recruited from patients admitted to acute medical services who
have VTE risk factors qualifying them for anticoagulant prophylaxis according to
AACP Guidelines [11].
Subjects meeting the inclusion/exclusion criteria would be randomized to receive
either a standard anticoagulant per AACP Guidelines (i.e., LMWH, low dose heparin,
or fondaparinux) or a low-VTE-risk diet regimen. The diet (Mediterranean, vegetarian
or vegan per the patient’s choice) would be recommended for the entire duration of
the trial, but compliance would be left to the discretion of the patient and treating
physician. This flexibility in the diet arm assures that the diet intervention would not
Cundiff et al. Theoretical Biology and Medical Modelling 2010, 7:31
http://www.tbiomed.com/content/7/1/31
Page 18 of 24be a burden to patients. Flexibility in administering the low VTE diet is reasonable,
since the RCTs are in large part testing the safety and efficacy of standard anticoagula-
tion prophylaxis and treatment, and the low VTE diet would not be expected to do
harm.
All outcomes will be recorded into the patients’ medical records. In addition, follow-
up RCT-related visits or calls as appropriate will be conducted approximately every
10 days up to 60 days after anticoagulation prophylaxis is completed, to determine if
any of the primary or secondary safety or efficacy outcomes had occurred. Compliance
with the low VTE risk diet will also be assessed, asking each patient to estimate his/
her compliance on a scale of 0 - 100, with ‘0’ representing completely non-compliant
and ‘100’ representing completely compliant. If follow-up takes place before discharge
from the hospital, the information will be entered into the patient’s medical record and
separate data collection forms; if the follow-up takes place after discharge, the infor-
mation will be recorded on to separate data collection forms.
The data collection forms will be assessed by study monitors at each participating
medical center and reviewed by the responsible investigator at each medical center
before anonymized data are sent to the study PI.
As noted above, we would use the overall death rate as the primary efficacy end-
point. Since the aforementioned Cochrane Review showed that prophylactic anticoagu-
lation does not significantly reduce FPE rates or overall deaths in acute medical
patients (for anticoagulation versus placebo, FPE: 0.94 [0.82, 1.07] and overall deaths:
RR 0.95 [0.83, 1.07] [87]), a 50% non-inferiority tolerance is reasonable. The death rate
in this Cochrane review was about 5% with or without anticoagulant prophylaxis. So
with anticoagulant prophylaxis, the primary safety endpoint (overall bleeding) and the
primary efficacy endpoint (overall mortality) would each be expected to occur in about
5% of patients. Expecting that the absence of anticoagulation and a low VTE diet can
reduce the incidence of the total bleeding safety endpoint down to 2.5% with no
change in efficacy, about 1,400 subjects would be required in each treatment group in
order to have 80% power to meet both co-primary hypotheses (superior safety and
non-inferior efficacy).
Conclusion
Because of the bleeding and ‘rebound hypercoagulability’ risks of anticoagulation for
VTE prophylaxis and the possibility that a low VTE risk diet might reduce the inci-
dence of hospital-acquired VTE; randomized controlled non-inferiority clinical trials
should be undertaken to compare standard anticoagulant treatment with a potentially
low VTE risk diet (vegetarian, vegan, or Mediterranean) for VTE prophylaxis of medi-
cal and surgical patients. Likewise for VTE treatment, a randomized non-inferiority
clinical trial comparing standard anticoagulation treatment with a low VTE risk diet
should also be considered. We call upon the U. S. National Institutes of Health and
the British National Institute for Health and Clinical Excellence to design and fund
those trials.
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